Results 111 to 120 of about 2,398,808 (296)

Supplementary Fig. S1 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Fig.
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source

LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer [PDF]

, 2019
The present invention relates to a special type of non-internalizing binding moiety- drug-conjugates that specifically target LGALS3BP. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to ...
Francesco GIANSANTI, Roberta GENTILE, Emily CAPONE, Gianluca Sala, Enza PICCOLO, Rodolfo Ippoliti, Stefano Iacobelli, Sara PONZIANI   +7 more
core   +2 more sources

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL

Cancer Management and Research, 2023
Jing Zhang, Yan Gu, Baoan Chen Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People’s Republic of ChinaCorrespondence: Baoan Chen, Department of Hematology, Zhongda Hospital, School of Medicine ...
Zhang J, Gu Y, Chen B
doaj  

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

Antibody drug conjugates in the clinic

Bioengineering & Translational Medicine
Abstract Antibody‐drug conjugates (ADCs), chemotherapeutic agents conjugated to an antibody to enhance their targeted delivery to tumors, represent a significant advancement in cancer therapy. ADCs combine the precise targeting capabilities of antibodies and the potent cell‐killing effects of chemotherapy, allowing for enhanced ...
Edidiong Udofa, Disha Sankholkar, Samir Mitragotri, Zongmin Zhao   +3 more
openaire   +3 more sources

Computational selection of antibody-drug conjugate targets for breast cancer

, 2015
The selection of therapeutic targets is a critical aspect of antibody-drug conjugate research and development. In this study, we applied computational methods to select candidate targets overexpressed in three major breast cancer subtypes as compared ...
Fauteux, Fran\ue7ois, Phan, Sieu, O'Connor-McCourt, Maureen, Pan, Youlian, Jaramillo, Maria L., Famili, Fazel, Hill, Jennifer J.   +6 more
core  

Supplementary Table S2 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Table S2 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic ...
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region

FEBS Open Bio, EarlyView.
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson, Anja H. Schiemann, Evelyn Sattlegger   +2 more
wiley   +1 more source

Supplemental Figure Legend from Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies

, 2015
Supplemental Figure Legend from Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other ...
Cecile Rouleau (14974161), Bruce C. Horten (15072706), Robert Smale (14974167), Stephanie D. Roth (15072697), Steven M. Schmid (15072709), Roy Krumbholz (328645), Kenneth J. Munroe (15072700), Jay Harper (203272), Tessa L. Green (15072703), Beverly A. Teicher (9030386), Diego A. Gianolio (1831690)   +10 more
core   +1 more source